Penn Capital Management Company, LLC / HALO
Penn Capital Management Company, LLC’s Halozyme Therapeutics Inc Position
Does Penn Capital Management Company, LLC own Halozyme Therapeutics Inc (HALO)? Not currently — the last reported position was 266.2K shares worth $15M in Q3 2024; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$15M
Q3 2024
Shares
266.2K
% of Portfolio
+1.40%
Quarters Held
19
position exited
Position History HALO
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q3 2024 | 266.2K | $15M | +1.40% |
| Q2 2024 | 300.7K | $16M | +1.50% |
| Q1 2024 | 272.6K | $11M | +0.99% |
| Q4 2023 | 279.5K | $10M | +0.95% |
| Q3 2023 | 324.7K | $12M | +1.28% |
| Q2 2023 | 286.5K | $10M | +1.00% |
| Q1 2023 | 285.7K | $11M | +1.11% |
| Q4 2022 | 286.5K | $16M | +1.67% |
| Q3 2022 | 65.4K | $3M | +1.67% |
| Q2 2022 | 299.8K | $13M | +1.42% |
| Q1 2022 | 224.8K | $8M | +0.86% |
| Q4 2021 | 279.4K | $11M | +1.14% |
| Q3 2021 | 290.4K | $12M | +1.19% |
| Q2 2021 | 276.9K | $13M | +1.22% |
| Q1 2021 | 268.9K | $11M | +1.17% |
| Q4 2020 | 241.4K | $10M | +1.30% |
| Q3 2020 | 292.6K | $8M | +0.98% |
| Q2 2020 | 290.1K | $8M | +1.02% |
| Q1 2020 | 284.1K | $5M | +0.84% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Penn Capital Management Company, LLC’s full portfolio or all institutional holders of HALO.